EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges

Umme Sabrina Haque, Toshifumi Yokota iD

Genes · 2024

DOI: 10.3390/genes15080999 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Umme Sabrina Haque und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Genetic Therapy, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Alberta Faculty of Medicine and Dentistry, the Canadian Institutes of Health Research, the Friends of Garrett Cumming Research Funds, HM Toupin Neurological Science Research Funds, Muscular Dystrophy Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is a severe genetic disorder characterized by the loss of motor neurons, leading to progressive muscle weakness, loss of mobility, and respiratory complications. In its most severe forms, SMA can result in death within the first two years of life if untreated. The condition arises from mutations in the SMN1 (survival of motor neuron 1) gene, causing a deficiency in the survival motor neuron (SMN) protein. Humans possess a near-identical gene, SMN2, which modifies disease severity and is a primary target for therapies. Recent therapeutic advancements include antisense oligonucleotides (ASOs), small molecules targeting SMN2, and virus-mediated gene replacement therapy delivering a functional copy of SMN1. Additionally, recognizing SMA’s broader phenotype involving multiple organs has led to the development of SMN-independent therapies. Evidence now indicates that SMA affects multiple organ systems, suggesting the need for SMN-independent treatments along with SMN-targeting therapies. No single therapy can cure SMA; thus, combination therapies may be essential for comprehensive treatment. This review addresses the SMA etiology, the role of SMN, and provides an overview of the rapidly evolving therapeutic landscape, highlighting current achievements and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalGenetic TherapySurvival of Motor Neuron 1 ProteinSurvival of Motor Neuron 2 ProteinOligonucleotides, AntisenseHumansAnimalsGene Targeting

Stichwörter der Autor:innen

SMN proteinSMN2antisense oligonucleotide (ASO)combination therapygene therapynusinersenonasemnogenerisdiplamsmall moleculespinal muscular atrophy (SMA)survival of motor neuron 1 (SMN1)

Substanzen

Survival of Motor Neuron 1 ProteinSurvival of Motor Neuron 2 ProteinOligonucleotides, AntisenseSMN1 protein, humanSMN2 protein, human

Autor:innen und Institutionen

  • Department of Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
  • Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
  • The Friends of Garrett Cumming Research & Muscular Dystrophy Canada HM Toupin Neurological Science Research, Edmonton, AB T6G 2H7, Canada.

ORCID-Profile: Toshifumi Yokota

Förderung

  • University of Alberta Faculty of Medicine and Dentistry, the Canadian Institutes of Health Research, the Friends of Garrett Cumming Research Funds
  • HM Toupin Neurological Science Research Funds
  • Muscular Dystrophy Canada
  • Women and Children’s Health Research Institute

Zitieren

APA

Haque, U. S., & Yokota, T. (2024). Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. Genes. https://doi.org/10.3390/genes15080999

Vancouver

Haque US, Yokota T. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. Genes. 2024. doi:10.3390/genes15080999

BibTeX
@article{Haque2024,
  author = {Haque, Umme Sabrina and Yokota, Toshifumi},
  title = {Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15080999}
}
Kostenlos starten →